Two monoclonal antibodies appeared safe and tolerable when administered alone or in combination to newborns exposed to HIV, according to a proof-of-concept study presented at the International AIDS ...

THE National Aids Council (NAC)’s programmes meant to fight against HIV and Aids were heavily derailed after United States (US) President Donald Trump early this year signed an executive order ...

WHO recommends twice-yearly injectable lenacapavir for HIV prevention, expanding PrEP options for key populations.

Popular global HIV/AIDS program PEPFAR has been spared as Congress passes a package with billions of dollars in spending cuts ...

A decade ago, the global community established the goal to end AIDS as a public health threat by 2030 through reducing new HIV infections and AIDS-related deaths by 90% from 2010 levels.1 Progress has ...

The program known as PEPFAR is one of the most effective and popular U.S. foreign aid projects in history, and the government ...

New data demonstrated that long-acting cabotegravir was preferable to daily dolutegravir/lamivudine in treatment-naive people living with HIV.

New WHO guidelines endorse long-acting injectable lenacapavir for HIV prevention, Medicines Patent Pool expands licence for long-acting injectable cabotegravir for treatment, and Merck’s once-monthly ...

Even with the HIV prevention waters now dominated by Gilead Science’s Yeztugo (lenacapavir), Merck & Co. is not afraid to swim deeper in. | Even with the HIV prevention waters now dominated by Gilead ...

Ending USAID could lead to the deaths of 14 million people over the next five years, an analysis from a medical journal ...

Breeze, a Louisville nonprofit that supports LGBTQ+ young adults, paused its free HIV testing services due to federal funding ...

PrEP vs. PEP: Thanks to changes in technology there are many medications designed for HIV, but how much do you know about them?